Currently submitted to: JMIR Preprints
Date Submitted: Nov 19, 2025
Open Peer Review Period: Nov 19, 2025 - Nov 4, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Global Biobanks in Enhancing Risk Prediction and Prevention through Digital Longevity: Narrative Review
ABSTRACT
Biobanks are recognised as lucrative health research resources due to their extensive and in-depth data availability, which allows researchers to draw correlations between various genetic, lifestyle, and health information and future disease incidence. As prospective data sources collect genetic and lifestyle information for several hundred thousand participants across various age categories, biobanks are important datasets in designing novel healthcare approaches. Within the realm of cardiometabolic ageing, which refers to the age related decline in the function of cardiovascular and metabolic systems, the conceptualisation of a systems medicine-based approach known as P4 (Predictive, Preventive, Personalised, Participatory) medicine has provided an interesting framework to tackle these metabolic illnesses in tandem with digital longevity tools that serve as vessels to deliver interventions across large populations. Therefore, this review aims to critically discuss how digital longevity informed by biobank data is vital in improving risk prediction, with a focus on cardiometabolic ageing.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.